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ABSTRACT
Edoxaban is the fourth non-vitamin K antago-
nist oral anticoagulant now available for clinical
use in the prevention of stroke/systemic embo-
lism in atrial fibrillation (AF) and in the treat-
ment of venous thromboembolism (VTE), after
the completion of large-scale randomized com-
parative clinical trials with the vitamin K
antagonist warfarin. Edoxaban has some pecu-
liar pharmacological properties and outcome
data. Here a group of experts in AF and VTE
answers a set of questions on its practical use,
trying to define the profile of patients that
would be most appropriate for its use.
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INTRODUCTION
Edoxaban is the fourthnon-vitaminKantagonist
oral anticoagulant (NOAC) approved for clinical
use for prevention of stroke/systemic embolism
in atrial fibrillation (AF) and for the treatment of
venous thromboembolism (VTE) after the com-
pletion of large-scale randomized comparative
clinical trials with the vitamin K antagonists
(VKA)warfarin. In addition to demonstrations of
efficacy and safety, edoxaban has some peculiar
pharmacological properties that make its use an
interesting treatment option for patients requir-
ing anticoagulant treatment.
This manuscript, written by a group cardiol-
ogists, hematologists, and internists with a
specific interest in antithrombotic therapies,
summarizes the main properties of edoxaban;
formulates a set of practical questions selected by
the group, with an eye to profiles of patients in
whom the use of the drug appears to be particu-
larly suitable; and provides answers to such
questions with the aim of helping physicians to
properly administer this agent in the appropriate
patients. This paper does not aim to make direct
comparisons of edoxabanwithotherNOACs, but
is intended to help delineate reasons supporting
the use of this specific drugs in specific patient
categories, highlighting possible advantages in
specific patient subsets or therapeutic areas
where the use of the drug is supported by scien-
tific evidence. References to other NOACs are
therefore done only when opportune to delin-
eate the specificity of this drug.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
PHARMACOLOGICAL PROFILE
OF EDOXABAN IN COMPARISON
WITH OTHER NOACS
Like rivaroxaban and apixaban, edoxaban is a
selective, direct inhibitor of coagulation factor
Xa,whereas dabigatran selectively inhibits factor
IIa (thrombin). Factor Xa inhibition in the
coagulation cascade leads to decreased thrombin
generation, and therefore a reduction in throm-
bus formation and progression. The pharma-
cokinetics of edoxaban is dose-dependent up to
doses of 120–150 mg [1]. Peak plasma concen-
trations are reached after 1–2 h from the admin-
istration [1]. The bioavailability is approximately
62%. At variance from rivaroxaban, the systemic
exposure to edoxaban is not apparently affected
by food [1]. In plasma, edoxaban primarily cir-
culates in an unchanged form, with minimal
metabolism [1]. Approximately 50% of the drug
is eliminated in the urine, and approximately
50% in the feces [1]. Over 70% of edoxaban is
cleared unchanged, with an elimination half-life
of 10–14 h [1]. Renal impairment increases the
systemic exposure to the drug. This increase is on
average 32% for an estimated creatinine clear-
ance (eCrCl) 51–80 mL/min; and[72% for an
eCrCl\30 mL/min, in comparison with subjects
with a normal renal function [1]. No major
changes in edoxaban pharmacokinetics have
been shown with mild-to-moderate hepatic
impairment [1]. Albeit limited in number, some
drug–drug interactions may occur, mainly
resulting from interference with the P-glycopro-
tein efflux transporter, which is responsible for
the transport of edoxaban across the intestinal
mucosa [1]. P-glycoprotein inhibitors, such as
dronedarone, ketoconazole, erithromycin, and
cyclosporine, are associated with increased
edoxaban plasma concentrations, and the con-
comitant use of edoxaban with these agents
requires dose adjustment (i.e., a halving of the
dose) [2]. Amiodarone, however, hadnoeffect on
the relative efficacy and safety of edoxaban
60 mg [3]. Conversely, the P-glycoprotein indu-
cer rifampin has been shown to significantly
decrease edoxaban plasma concentrations and
should therefore be used with caution. The
interaction with cytochrome P3A4 is minimal.
Criteria for dose reduction of edoxaban in rela-
tion to clinical and pharmacokinetic variables
have been validated in a specific study assessing
the blood concentration and factor Xa activity
[4].
An overview of edoxaban pharmacology
compared with other NOACs is provided in
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Table 1. Because of the better safety profile
compared with VKAs, leading to a consistent
saving in direct healthcare costs, all NOACs are
likely cost-effective. This is probably also true
with edoxaban [5]. Edoxaban price conditions
in Europe will be similar to that of other
NOACs.
A specific antidote is not yet available for
edoxaban, as well as for the other Xa inhibitors.
Andexanet alfa, an antidote against factor Xa
inhibitors, is currently under review by the
European Medicinal Agency (EMA) for reversal
of its pharmacological action [6]. The infusion
of a 4-factor prothrombinase complex concen-
trate (PCC) at 50 IU/kg has been shown to
reverse the effects of edoxaban 30 min after
completing its administration [7].
THE REGISTRATION STUDIES
ENGAGE AF-TIMI 48
In the ENGAGEAF-TIMI 48 trial [8], edoxaban, at
the initial doses of 60 and 30 mgonce daily (OD),
was compared with adjusted-dose warfarin, tar-
geted to an international normalized ratio (INR)
of 2.0–3.0, for the prevention of stroke/systemic
embolism in patients with non-valvular atrial
fibrillation (NVAF). The choice for the OD
administration regimen for edoxaban derives
from a randomized, dose-ranging, warfarin-con-
trolled, phase II study involving 1146 patients
with AF. In this study, the OD regimen was
shown to be safer (with less bleeding) than the
twice-daily (BID) regimen [9].
The ENGAGE AF-TIMI 48 trial [8] was a ran-
domized, double-blind, multicenter,
placebo-controlled trial. The population enrol-
led was of 21,105 patients, followed up for a
median of 2.8 years, making ENGAGE AF-TIMI
48 the study with the largest population and the
longest follow-up in comparison with other
registration trials with NOACs in NVAF [10–12].
The median time in therapeutic range (TTR) in
the warfarin arm was 68.4%, which was the
highest among the studies with NOACs in
NVAF [8, 10–12]. The stroke risk profile of the
ENGAGE AF-TIMI 48 population was interme-
diate between the relatively lower risk of RE-LY
[10] and ARISTOTLE [12] and the relatively
higher risk of ROCKET-AF [11], as shown by a
mean CHADS2 score of 2.8 [8]. The study pro-
tocol demanded the halving of the edoxaban
dose when factors known to increase plasma
concentrations, and therefore conceivably the
risk of bleeding, were present. These included
an eCrCl 30–50 mL/min; or a body weight
B60 kg; or the concomitant use of potent P--
glycoprotein inhibitors (such as verapamil,
quinidine, or dronedarone). At variance from
the other registration trials, such a dose adjust-
ment could be done both at randomization and
during the study, and was reversible in case of a
reversal of the conditions that had demanded
the dose reduction [8].
For the primary efficacy endpoint of stroke/
systemic embolism, the statistical analysis
Table 1 Main pharmacological characteristics of the non-vitamin K-antagonist oral anticoagulants (NOACs) used in atrial
ﬁbrillation and venous thromboembolism
Dabigatran Rivaroxaban Apixaban Edoxaban
Target Factor IIa (thrombin) Factor Xa Factor Xa Factor Xa
Prodrug Yes No No No
Bioavailability 0.06 100% (with food) 0.5 0.62
Plasma protein binding 0.35 0.93 0.87 0.5
Time to peak 1.5–2 h 2–3 h 2–3 h 1–2 h
Elimination half-life 12–17 h 5–9 h (young), 11–13 h (elderly) 12 h 10–14 h
Route of clearance 80% renal 35% renal 27% renal 50% renal
622 Adv Ther (2017) 34:620–637
tested the non-inferiority of edoxaban versus
warfarin [8]. Table 2 reports the results of the
comparison versus warfarin of the edoxaban
daily dose of 60 mg, reduced to 30 mg in the
selected populations specified above; this—
herein indicated as 60/30 mg—is now the rec-
ommended dose approved by American and
European regulatory authorities. Edoxaban
60/30 mg proved to be non-inferior to warfarin
in the prevention of stroke and systemic
embolism, with a trend towards superiority [rate
of 1.50% per year in the warfarin group vs
1.18% in the edoxaban 60/30 group; hazard
ratio (HR) vs warfarin, 0.79; 97.5% confidence
interval (CI) 0.63–0.99; P\0.001 for noninferi-
ority]. Edoxaban 60/30 mg also significantly
reduced cardiovascular death. As to the primary
safety endpoint of major bleeding, edoxaban
60/30 mg proved significantly superior to
warfarin (rate of 3.43% per year with warfarin vs
2.75 with edoxaban 60/30; HR vs warfarin, 0.80;
95% CI 0.71–0.91; P\0.001).
Hokusai-VTE
The Hokusai-VTE study [13] was a randomized,
double-blind, non-inferiority trial, aimed at
assessing the efficacy and safety of edoxaban for
the treatment of VTE. In this study, patients with
objectively diagnosed deep vein thrombosis
(DVT) and/or pulmonary embolism (PE) received
an initial therapy with open-label enoxaparin or
unfractionated heparin for at least 5 days. Edox-
aban or warfarin were administered in a dou-
ble-blind, double-dummy fashion. Edoxaban or
placebo was started after the discontinuation of
initial heparin. Warfarin or placebo was started
concurrently with the study regimen of heparin,
with adjustment of the dose tomaintain the INR
between 2.0 and 3.0. The standard edoxaban
60 mg OD dose was reduced to 30 mg OD in
patients with eCrCl between 30 and 50 mL/min
or a body weight\60 kg, or the concomitant use
of potent P-glycoprotein inhibitors, as for
ENGAGE AF-TIMI 48. The anticoagulant treat-
ment was given for at least 3 months and up to
12 months, at the discretion of the investigators.
The primary study outcome was the recur-
rence of symptomatic VTE at 12 months; the
primary safety outcome was the incidence of
major and clinically relevant non-major bleed-
ing. A total of 8292 patients were enrolled in the
study, of whom 3319 had PE. The median
duration of heparin treatment was 7 days, the
INR was in the therapeutic range for 63.5% of
the time, and 40% of patients were treated for
12 months. At 12 months, recurrent VTE
occurred in 3.2% of the edoxaban patients and
in 3.5% of the warfarin patients (HR 0.89; 95%
CI 0.70–1.13; P for non-inferiority\0.001). The
safety outcome occurred in 8.5% and in 10.3%
of patients, respectively (HR 0.81; 95% CI
0.71–0.94; P for superiority 0.004). In PE
patients with NT-proBNP higher than 500 pg/
mL (approximately 28% of the PE population),
the primary efficacy outcome was reduced from
6.2% in the warfarin group to 3.3% in the
edoxaban group (HR 0.52; 95% CI 0.28–0.98).
Table 2 Main efﬁcacy and safety outcomes with edoxaban
60/30 mg vs warfarin in ENGAGE AF-TIMI 48
HR (95% CI) P value
Stroke/SEE
mITT 0.79 (0.63–0.99) \0.001b
ITT 0.87 (0.73–1.04)a 0.08b
Stroke 0.88 (0.75–1.03) 0.11
Hemorrhagic 0.54 (0.38–0.77) \0.001
Ischemic 1.00 (0.83–1.19) 0.97
Death
All-cause 0.92 (0.83–1.01) 0.08
CV 0.86 (0.77–0.97) 0.013
Myocardial infarction 0.94 (0.74–1.19) 0.60
Bleeding
Major 0.80 (0.71–0.91) \0.001
Life-threatening 0.51 (0.38–0.70) \0.001
Major or CRNM 0.86 (0.80–0.92) \0.001
SEE systemic embolic event, mITT modiﬁed inten-
tion-to-treat, ITT intention-to-treat, HR hazard ratio, CI
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Among patients who qualified for the 30 mg
dose of edoxaban (approximately 17% of the
entire population), recurrent VTE occurred in
3.0% of edoxaban patients and 4.2% of warfarin
patients (HR 0.73; 95% CI 0.42–1.26), and the
safety outcome in 7.9% and 12.8%, respectively
(HR 0.62; 95% CI 0.44–0.86) (Fig. 1). In sum-
mary, Hokusai-VTE showed that a single daily
dose of edoxaban is as effective as and safer than
warfarin after an initial course of heparin for the
treatment of VTE. Hokusai-VTE was the largest
phase III study conducted in this setting, the
first to assess a flexible dosing regimen, and the
first to assess the severity of PE using a bio-
marker of right ventricular dysfunction. The
favorable efficacy and safety profile of edoxaban
was confirmed in the subgroups of patients




Once Daily Administration: Which
Patients Might Benefit Most From It?
The NOAC dosing regimen, specifically whether
OD or BID, is part of the decision-making to
select the most appropriate drug for the specific
patient. For all NOACs, because of their short
half-life, non-adherence is a more serious
problem than for warfarin—see the higher rate
of thromboembolic events that occurred in the
Fig. 1 Efﬁcacy and safety outcomes in patients who
qualiﬁed for the 30 mg dose of edoxaban. In the
Hokusai-VTE study edoxaban was administered at the
60 mg once daily dose, reduced to 30 mg once daily in
patients with a creatinine clearance between 30 and
50 mL/min or a body weight B60 kg. In patients requiring
dose reduction, edoxaban conﬁrmed non-inferiority in
terms of efﬁcacy and superiority in terms of safety,
compared with warfarin. VTE venous thromboembolism,
OD once daily, RRR relative risk reduction, MB major
bleeding, CRNMB clinically relevant non-major bleeding
624 Adv Ther (2017) 34:620–637
discontinuation phase of rivaroxaban in the
ROCKET-AF trial [11]. Therefore, all measures
maximizing adherence should be welcome and
of advantage to the patients. In cardiovascular
patients, the OD administration has been
demonstrated to be associated with a greater
adherence compared with BID dosing in
patients with diabetes and hypertension [14]
and, specifically, in patients with AF [15]. This is
likely to be true also for the NOACs, provided
that OD regimens ensure efficacy and safety at
least similar to BID regimens [16]. Among the
NOACs, edoxaban has been tested in a phase II
dose-finding trial in AF, demonstrating lower
bleeding rates (i.e., superior safety) with the OD
regimen than with the BID regimen with the
same total daily dose [9]. OD administration is
also used for all VKAs: therefore, having a
NOAC that can be given OD like VKAs elimi-
nates a possible reservation bias in the patient
already used to anticoagulation with a VKA. OD
dosing in AF patients and for the management
of most durations of VTE treatment is also
possible for rivaroxaban. With these premises,
the results of phase III registration trials [8, 13]
indicate that the clinical efficacy of edoxaban is
not compromised by OD dosing.
Skipping one pill of an OD drug for NOACs,
all with a half-life of approximately 12 h, might,
on the other hand be of greater detrimental
effect than for a BID drug. Recent results, how-
ever, have not in general lent much support to
the hypothesis that skipping one pill with an
OD drug has a greater detrimental effect than
for a BID drug [17]. In summary, although the
issue of OD vs BID should be seen in its com-
plexity [16] (see also the higher possible risk of
overdosing with the accidental overingestion of
one or several pills of an OD vs a BID drug), the
authors concluded that the advantages of
achieving better adherence with an OD drug
outweigh the higher theoretical risks deriving
from skipping doses or overdosing.
From everyday practice, several patient cat-
egories would appear to probably benefit from
an OD administration. These include [16]
• Patients with comorbidities, needing to take
many tablets per day
• Elderly people, commonly using complex
drugs regimens with multiple drugs, which
can negatively affect medication adherence
• Patients with suspected low adherence
• Young active workers, reluctant to take
medications
Few Interactions with Other Drugs:
A Particular Advantage for Edoxaban?
As detailed in the general section above, edox-
aban has a very minor (\4%) proportion of
metabolism through the cytochrome P450 sys-
tem compared with the other Xa factor inhibi-
tors [18, 19], suggesting that it may have fewer
drug–drug interactions compared with other
NOACs. Indeed, a CYP3A4-dependent elimina-
tion is involved in the hepatic clearance of
rivaroxaban and apixaban [20]. This means that
strong CYP3A4 inhibition or induction may
affect plasma concentrations of these two
NOACs. When strong inhibitors of both
CYP3A4 and P-glycoprotein (dronedarone or
azole antimycotics, such as itraconazole, keto-
conazole, posaconazole, voriconazole) are
administered, plasma levels of rivaroxaban and
apixaban can increase [21]. In patients needing
these drugs, edoxaban is the only FXa inhibitor
not contraindicated, although a dose reduction
from 60 to 30 mg/day is suggested. Similarly,
rivaroxaban and apixaban are contraindicated
in combination with strong inducers of P-gly-
coprotein and CYP3A4 (such as rifampicin,
carbamazepine, phenobarbital, phenytoin, St
John’s wort), which strongly reduce plasma
levels [22]. The need for using such drugs may
represent a contraindication to the simultane-
ous use of those NOACs (Table 3). Conversely,
the edoxaban label mentions that co-adminis-
tration is possible for edoxaban in such cases,
despite expected slightly decreased plasma
level. Minor interactions of edoxaban have been
noted with amiodarone, verapamil, and quini-
dine; however, after the analysis of phase III
clinical trial data, this interaction was consid-
ered not clinically relevant, and no dose
reduction is thus recommended in the label.
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Association with Antiplatelet Drugs: How
Safe is Edoxaban?
Because of their impact on hemostasis, the
association of NOACs with other anticoagu-
lants, platelet inhibitors (aspirin, clopidogrel,
ticlopidine, and others), and non-steroidal
anti-inflammatory drugs increases the bleeding
risk by at least 60% [23–25]. This estimate is
similar to what was previously described for the
association of these drugs with VKAs [26].
Therefore, the need for such associations needs
to be carefully assessed, balancing benefits and
risks in each individual patient. In the ENGAGE
AF-TIMI 48 trial, the concomitant use of single
antiplatelet therapy (SAPT), when judged nec-
essary by the prescribing physicians, did not
alter the relative efficacy of edoxaban compared
with warfarin [edoxaban vs warfarin without
SAPT: HR 0.94, 95% CI 0.77–1.15, with SAPT:
HR 0.70, 95% CI 0.50–0.98, P for interaction
(Pint) 0.14]. Notably, when compared with
warfarin, edoxaban 60/30 mg OD featured less
overall bleeding, including intracranial hemor-
rhage and life-threatening bleeding, both in
patients receiving aspirin or other antiplatelet
agents (HR 0.46, 95% CI 0.27–0.79; and HR
0.56, 95% CI 0.35–0.88, respectively) and in
patients who were not receiving these drugs (HR
0.47, 95% CI 0.31–0.71 and HR 0.56, 95% CI
0.39–0.79, respectively). The concurrent use of
aspirin increased the risk of having major
bleeding events in all treatment groups, but did
not change the relative risk compared with
warfarin; major bleeding was lower with edox-
aban than warfarin both without SAPT (HR
0.80, 95% CI 0.68–0.95) and with SAPT (HR
0.82, 95% CI 0.65–1.03, Pint 0.91) [27]. In
patients taking aspirin, a similar benefit of
edoxaban compared with warfarin was observed
Table 3 Interaction between NOACs and strong inhibitor/inducers of both CYP3A4 and P-glycoprotein Modiﬁed from
[16]
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for all the efficacy endpoints, all the safety
endpoints, and for the net clinical benefit
evaluation, which combined death, stroke, sys-
temic embolic events, and major bleeding
(edoxaban 60/30 mg without SAPT HR 0.82,
95% CI 0.71–0.95 and with SAPT HR 0.89, 95%
CI 0.81–0.98, Pint 0.35). A lower occurrence of
bleeding was observed in the edoxaban
60/30 mg group, without significant excess in
all type strokes or ischemic strokes compared
with warfarin [27] (Fig. 2). These data broadly
confirm the safety profile of NOACs compared
with warfarin when administered together with
antiplatelet drugs, and inform physicians that,
when the dangerous coadministration of anti-
platelet drugs and an anticoagulant is deemed
necessary, then NOACs, including edoxaban,
are overall a safer choice than warfarin.
Is Edoxaban Attractive in Patients
with Atrial Fibrillation and Chronic
Kidney Disease?
Chronic kidney disease (CKD) is common in
patients with AF, even if clinically not overt
[28], with 11–23% of AF patients presenting an
impairment in renal function, of variable degree
[29]. In the ENGAGE AF-TIMI 48 trial, patients
with an eCrCl\30 mL/min (assessed with the
Cockcroft–Gault formula) were not enrolled [8],
similarly to the other trials on NOACs in AF
[10–12]. The labeling and the summary of pro-
duct characteristics (SmPc) of edoxaban [2]
report a non-indication for this drug if the
eCrCl is\15 mL/min; this may allow a window
of safety should the eCrCl fall below the 30 mL/
min threshold during treatment [22], similar to
Fig. 2 Major bleeding and net clinical outcomes of HD
edoxaban vswarfarin in patients with andwithout antiplatelet
therapy. Patients taking aspirin in the higher dose edoxaban
once daily regimen group had a lower rate of major bleeding
and a net clinical beneﬁt (NCB), comparedwith those treated
with warfarin. High dose refers to edoxaban 60 mg, reduced
to 30 mg in patients speciﬁcally qualifying for dose reduc-
tion (otherwise designated high-dose edoxaban regimen,
HDER). HD high dose, APT antiplatelet therapy, SEE
systemic embolic event, HR hazard ratio, P int P for
interaction
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what is possible for rivaroxaban and apixaban
[22]. For edoxaban, a reduction of the standard
dose of 60 mg OD (the dose approved by regu-
latory agencies) to 30 mg OD is indicated when
at least one of the following criteria is satisfied:
eCrCl from 30 to 50 mL/min; or body weight
B60 kg; or the concomitant use of potent P--
glycoprotein inhibitors (such as verapamil,
quinidine, or dronedarone) [8]. Similar to
apixaban, but at variance from rivaroxaban and
dabigatran, the application of the dose reduc-
tion criterion implies a more considerable
(50%)—and therefore possibly safer—reduction
of the dose than that occurring with rivaroxa-
ban and dabigatran (for which the dose reduc-
tion is 25% and 27% (from 20 to 15 mg OD and
from 150 to 110 mg BID, respectively).
The ENGAGE AF-TIMI 48 trial enrolled 4074
patients (1306 patients in the edoxaban
60/30 mg group) [4] with an eCrCl between 30
and 50 mL/min (19.3% of the trial population),
and this constitutes the largest group of patients
with renal insufficiency ever enrolled in a trial
with a NOAC [4, 8]. Patients eligible for the
edoxaban dose reduction had a complex clinical
profile, with a much higher risk of stroke/sys-
temic embolism, as well as of major bleeding,
compared with normal patients (1.7-fold
increased risk of stroke and 1.6 increased risk of
bleeding in the warfarin arm) [4]. It is note-
worthy that dose reduction did not alter the
efficacy of edoxaban compared with warfarin
(HR 0.81, 95% CI 0.58–1.13, P = 0.85), while the
risk of major bleeding was significantly reduced
(HR 0.63, 95% CI 0.50–0.81, P = 0.023) with the
higher-dose regimen (60/30 mg OD) of edoxa-
ban as compared with warfarin [4] (Fig. 3).
Direct comparisons between different NOACs
are not available, but a meta-regression analysis,
with all its intrinsic limitations [30], found that
in patients with moderate renal impairment the
risk of major bleeding with edoxaban 60/30 mg
OD was lower than that of dabigatran 150 mg
BID, dabigatran 110 mg BID, or rivaroxaban
20 mg OD, with no significant differences
compared with apixaban 5 mg BID. With regard
to efficacy (prevention of stroke/systemic
embolic events), no significant differences
could be detected between edoxaban 60/30 mg
OD and dabigatran 110 mg BID, dabigatran
150 mg BID, apixaban 5 mg BID, or rivaroxaban
20 mg OD [30]. In view of the data from
ENGAGE AF-TIMI 48, edoxaban, with the
appropriate dose reduction from 60 to 30 mg
OD, appears to be a quite reasonable option in
patients with NVAF and CKD with an eCrCl
between 30 and 50 mL/min.
Can Edoxaban be Suitable for Frail Elderly
Patients?
Most AF patients are elderly (C75 years old), and
increasing age is consistently a strong inde-
pendent risk factor for AF-associated stroke [31].
However, elderly patients are often underrep-
resented in randomized clinical trials.
Edoxaban might be a first-choice NOAC for
frail elderly patients for the following reasons:
• Edoxaban was widely tested in elderly
patients at both dosages. The ENGAGE
AF-TIMI 48 trial provides relevant data with
respect to the use of edoxaban in elderly
patients. Indeed [8], more than 8000 of the
enrolled patients were 75 years or older,
accounting for 40% of the 21,105 patients at
moderate-to-high thromboembolic risk
enrolled in the trial. The 60/30 mg edoxaban
regimen was non-inferior to warfarin in pre-
venting stroke/systemic embolism and was
associated with significantly less overall
major bleeding and intracranial hemorrhage
(ICH). Results were consistent in different age
and thromboembolic risk subgroups. Nota-
bly, edoxaban 60/30 mg also reduced the risk
of ischemic stroke in the older group, in
whom a risk reduction with edoxaban
60/30 mg compared with warfarin for ISTH
major bleeding (event rate %/year edoxa-
ban = 4; warfarin = 4.8; HR 0.83; 95% CI
0.70–0.99) and for ICH (event rate %/year
edoxaban = 0.5 warfarin = 1.2; HR 0.40; 95%
CI 0.26–0.62) was particularly evident in
patients aged C75 years. Furthermore, only
18% and 41% of patients aged C65 and
C75 years, respectively, received the reduced
dose in each randomization arm, thus
demonstrating that age alone does not
demand a dose reduction. A recent post hoc
628 Adv Ther (2017) 34:620–637
analysis of very elderly patients (age C80 and
age C85) showed that there were no signifi-
cant treatment interactions between age
groups and treatment for all major outcomes,
demonstrating the robustness of the findings
with edoxaban in the elderly. It should be
highlighted that this post hoc analysis
included a considerable number of very old
patients, being 3591 patients (17.0%) aged
C80 and 899 (4.3%) aged C85, thus reinforc-
ing the perception of edoxaban safety even in
very elderly patients [32] (Table 4).
• Edoxaban is safer than warfarin in patients at
risk of falls. An increased risk of falls and
associated neuropsychiatric disease is—be-
sides age—a risk factor for ICH in the elderly
[33, 34]. Patients with AF at high risk of falls
are at substantially increased risk of ICH,
especially traumatic ICH. However, because
of their high stroke rate, they still appear to
benefit from anticoagulant therapy if they
have multiple stroke risk factors [33, 34].
Indeed, while the risks of fall and ICH with
warfarin are often quoted as reasons to avoid
anticoagulation, it has been estimated that if
a patient has a 5% annual risk of stroke from
AF, he/she would need to fall at least 295
times to offset the benefit of oral anticoag-
ulation [35]. A subgroup analysis of the
ENGAGE AF-TIMI 48 trial demonstrated
that, in patients at increased risk of falls
[defined by any of the following eight crite-
ria at randomization: (1) prior history of
falls; (2) lower extremity weakness; (3) poor
balance; (4) cognitive impairment; (5) ortho-
static hypotension; (6) use of psychotropic
Fig. 3 Efﬁcacy and safety outcome with edoxaban dose
reduction. No dose reduction refers to the full dosage—
60 mg—for all patients who did not meet any criteria for
reducing the dosage, regardless of the randomization group
(warfarin or edoxaban). Conversely, dose reduction refers
to the halved dosage, 30 mg, for patients who met at least
one criteria for reducing the dosage (eCrCl 50–30 mL/
min, body weight B60 kg, concomitant use of P-gp
inhibitors), regardless of the randomization group
(warfarin or edoxaban). The dose reduction did not alter
the efﬁcacy of edoxaban compared with warfarin in the
prevention of stroke or systemic embolic event (HR 0.81,
95% CI 0.58–1.13, P int = 0.85), while the risk of major
bleeding was signiﬁcantly reduced (HR 0.63, 95% CI
0.50–0.81, P int = 0. 023). HD high dose, HR hazard
ratio, Edox edoxaban, SEE systemic embolic event, P int
P for interaction
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\80 1.6 1.4 0.87 (0.73–1.04) 0.97
C80 2.9 2.5 0.88 (0.64–1.20)
\85 1.7 1.5 0.88 (0.75–1.03) 0.56
C85 3.5 2.5 0.73 (0.40–1.33)
Ischemic stroke (years)
\80 1.1 1.1 1.03 (0.84–1.27) 0.54
C80 2.1 1.8 0.90 (0.63–1.30)
\85 1.2 1.2 1.01 (0.84–1.22) 0.5
C85 2.4 1.9 0.79 (0.39–1.60)
Hemorrhagic stroke (years)
\80 0.4 0.2 0.55 (0.37–0.82) 0.93
C80 0.8 0.4 0.53 (0.26–1.06)
\85 0.5 0.3 0.53 (0.37–0.76) 0.78
C85 0.8 0.5 0.64 (0.18–2.28)
Major bleeding (years)
\80 3 2.5 0.83 (0.71–0.96) 0.54
C80 6.2 4.6 0.75 (0.58–0.98)
\85 3.3 2.7 0.82 (0.72–0.94) 0.17
C85 8.8 5 0.58 (0.35–0.94)
ICH (years)
\80 0.7 0.4 0.49 (0.34–0.69) 0.64
C80 1.6 0.6 0.41 (0.22–0.77)
\85 0.8 0.4 0.46 (0.33–0.62) 0.62
C85 1.6 0.9 0.61 (0.20–1.88)
Fatal bleeding (years)
\80 0.3 0.2 0.57 (0.35–0.94) 0.79
C80 0.8 0.4 0.50 (0.21–1.15)
\85 0.4 0.2 0.52 (0.33–0.82) 0.45
C85 0.6 0.6 0.99 (0.20–4.91)
HR hazard ratio, CI conﬁdence interval, Pint P for interaction, ICH intracranial hemorrhage, SEE systemic embolic events
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drugs; (7) severe arthritis; or (8) dizziness],
edoxaban was associated with a sixfold lower
risk of ICH and fatal bleeds [36].
• Edoxaban dosage can be safely modified
when necessary. In the ENGAGE AF-TIMI
48 trial, dose adjustments were permitted
after randomization [8]. Since factors that
affect drug clearance may vary over time,
especially in the elderly, thus requiring a
dose reduction, the possibility of a dynamic
dose adjustment (meaning increase or
decrease of the daily dose in the presence
of changing body weight and eCrCl, besides
age), uniquely tested prospectively in the
ENGAGE AF-TIMI 48 trial, is a relevant factor
in the choice of the drug.
• Edoxaban can be administered relatively
safely in patients on aspirin. See Section ‘‘As-
sociation with Antiplatelet Drugs: How Safe
is Edoxaban?’’
• Edoxaban administration OD enhances
patients’ compliance compared with the
BID dosing necessary with two other NOACs
(see Section ‘‘Once Daily Administration:
Which Patients Might Benefit Most From
It?’’).
Can Edoxaban be Suitable for Patients
with Heart Failure?
The occurrence of AF may complicate the clin-
ical course of patients with heart failure (HF).
HF patients with concomitant AF have a poorer
outcome compared with HF patients without AF
[37]. Thus, prevention of AF-related complica-
tions may improve prognosis in this setting. In
the ENGAGE AF-TIMI 48 trial, the prevalence of
HF was 58% (n = 12,124), accounting for the
largest number of HF patients enrolled in the
phase III trials with NOACs [38]. In ENGAGE
AF-TIMI 48, HF patients had a higher risk pro-
file, with a higher CHADS2 score and increased
prevalence of prior myocardial infarction versus
those without HF [38]. This translated into
higher rates of adverse events, including car-
diovascular death and hospitalization for car-
diovascular causes.
Similarly to what was observed in random-
ized trials with the other NOACs, in ENGAGE
AF-TIMI 48 there was no interaction between
treatment assignment and the presence/absence
of HF. In particular, in patients with HF and
New York Heart Association (NYHA) class III–IV,
the use of edoxaban instead of warfarin led to a
17% relative risk reduction of stroke/systemic
embolism (HR 0.83, 95% CI 0.55–1.25), as well
as to a 21% (HR 0.79, 95% CI 0.54–1.17) and
65% (HR 0.35, 95% CI 0.14–0.88) lower risk of
major bleeding and ICH, respectively [38].
Because of the higher incidence of stroke/sys-
temic embolism in HF patients, the absolute
reduction of this endpoint by edoxaban was
more pronounced in this subgroup, with more
events prevented during the follow-up (3.5/
1000 patients/year vs 2.3/1000 patients/year in
patients without HF).
Edoxaban may thus represent a reasonable
option for patients with HF inasmuch as such
patients usually
• Have important frailty
• Are treated with multiple drugs, and their
compliance to treatment may thus be
improved with a NOAC given once daily
• Derive—for the same reason—advantages
from an anticoagulant agent having low
interference with other drugs frequently
used in the presence of HF, such as
amiodarone
• Have frequent fluctuations of creatinine
clearance, with the ENGAGE AF-TIMI 48
trial specifically demonstrating the safety of
edoxaban dynamic dose adjustments after
randomization
Are There Concerns About Edoxaban
in Patients with a Creatinine Clearance
‡95 mL/min?
In a post-hoc, exploratory analysis of the results
of the ENGAGE AF-TIMI 48 trial [8], a trend
towards decreased relative efficacy for ischemic
stroke prevention was observed in those
patients with an eCrCl [95 mL/min, with
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numerically higher rates in the edoxaban
60/30 mg group [39]. Rates of bleeding were on
the other hand lower with edoxaban 60/30 mg
OD in comparison to warfarin at all levels of
eCrCl [39]. Since about 50% of edoxaban is
excreted through the kidney, lower plasma
concentrations, and—as a consequence—a
lower anticoagulant effect, are conceivable in
such patients. On this basis, although absolute
event rates were very low in those with an eCrCl
[95 mL/min in both treatment groups, the
American Food and Drug Administration (FDA)
recommended to exclude patients with an eCrCl
[95 mL/min from edoxaban treatment [40].
This decision did not take into account the
exploratory nature of the subgroup analysis
performed here; the lack of randomization for
classes of renal function; and—most impor-
tantly—the particularly good and outlying per-
formance of warfarin in the normal renal
function subgroup in only this specific trial,
downsizing the effect of edoxaban [39]. Con-
trary to the FDA, the European Medicines
Agency (EMA) has not prohibited the use of
edoxaban in any classes of high creatinine
clearance. The phrasing has here been ‘‘edoxa-
ban should only be used in patients with NVAF
and high creatinine clearance after a careful
evaluation of the individual thromboembolic
and bleeding risk’’ [4]. There should be therefore
no limitation to edoxaban use in patients with
normal renal function, also in the light of the
preserved safety on major bleeding observed in
this category [39]. In addition, the net clinical
outcome (stroke/systemic embolism, ISTH
major bleeding, and the primary net clinical
outcome of stroke/systemic embolism, major
bleeding, and all-cause death) showed no sig-
nificant difference between edoxaban and war-
farin at higher levels of renal function, owing to
the preserved effect on bleeding and mortality
[39] (Fig. 4). The inconsistent interpretations of
the findings with edoxaban point, however, to a
need for further investigation into the efficacy
of all oral anticoagulants that are renally
cleared, with a focus on patients with normal or
super-normal renal clearance [39]. For edoxa-
ban, this will be done within the setting of a
formal post-authorization safety study (PASS)
now in a phase of advanced planning.
What are the Main Strengths of Edoxaban
in Patients with Acute Pulmonary
Embolism?
In the Hokusai-VTE study [13], edoxaban was
evaluated for the treatment of VTE patients.
Edoxaban was non-inferior to warfarin with
respect to efficacy and superior with respect to
safety, with fewer clinically significant bleeding
events (defined as major bleeding and clinically
relevant non-major bleeding). In all PE patients,
NT-proBNP was measured at baseline, and right
ventricular dysfunction was defined by levels of
500 pg/mL or higher. In this large subgroup of
patients with PE and right ventricular dysfunc-
tion the rate of recurrent VTE was 3.3% in the
edoxaban group (n = 454) and 6.2% in the
warfarin group (n = 484) (hazard ratio 0.52;
95% CI 0.28–0.98), with a significant reduction
in recurrent VTE (Fig. 5).
The main strengths of edoxaban in the
treatment of VTE can be summarized as follows:
• Edoxaban is a once daily dose regimen drug
(60/30 mg OD).
• In frail patients, with renal impairment
(eCrCL 15–50 mL/min) or low body weight
(B60 kg), the dose can be safely adapted to
30 mg OD.
Fig. 4 Net clinical outcome endpoints by exploratory
estimated creatinine clearance (eCrCl) subgroups. CrCl
(mL/min) at randomization was estimated with the
Cockcroft–Gault equation. P for interaction for treatment
by eCrCl is shown for the endpoint. CI conﬁdence
interval, HDER higher-dose edoxaban regimen, HR hazard
ratio. Asterisk HDER of 60 mg daily or 30 mg daily if dose
reduced for eCrCl B50 mL/min, weight B60 kg, or
potent P-glycoprotein inhibitor use
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• The drug is effective and safe in patients with
PE and right ventricular dysfunction.
It must be emphasized that treatment should
be initiated with standard dose of parenteral
heparin.
In conclusion, edoxaban is an attractive
regimen in a broad spectrum of PE patients and
can be a recommended approach, as it further
facilitates tailored treatment.
Is There a Clinical Benefit of the Heparin
Lead-In, as Indicated for Edoxaban,
in Patients with Pulmonary Embolism?
The first 5–10 days following the onset of a DVT
or PE account for the ‘‘acute phase’’ of the disease.
In this period, patients are at risk of thrombosis
extension, recurrence, hemodynamic failure,
and death [41]. Failure to rapidly achieve thera-
peutic levels of anticoagulation appears to be an
independent risk factor for recurrence [42],
which is about threefoldmore likely to bePE after
an initial PE than after an initial episode of DVT
[43]. This observation may justify an initial
intensive anticoagulant therapy and a more
aggressive treatment of PE. Guidelines recom-
mend starting treatment of PE with parenteral
anticoagulation [a lowmolecular weight heparin
(LMWH), or fondaparinux], concomitant initia-
tion of aVKA, and continuationof the parenteral
drug for at least 5 daysuntil the INR isC2.0 [44].A
recently published update of such guidelines
recommends anticoagulation with one of the
NOACs instead of VKAs, in the light of extensive
documentation of comparable efficacy and bet-
ter safety [45]. Edoxaban and dabigatran require
an anticoagulation lead-in with a LMWH for at
least 5 days, whereas a single-drug approachmay
be used with apixaban and rivaroxaban (with
dose adjustment in the first or 3 weeks of treat-
ment, respectively).Hokusai VTE in the only trial
that identified a subset of PE patients with right
ventricular (RV) dysfunction, defined as a level of
NT-proBNP [500 pg/mL. In these patients
edoxaban demonstrated a reduction of recurrent
VTE by 48% [13]. Edoxaban requires a short
course of LMWH and has the distinguished fea-
ture of being given once a day during the entire
course of treatment. Thus, the heparin lead-in
associated with edoxaban can be seen as an
effective and safe treatment in awide spectrumof
patients with PE, including those with right
ventricle dysfunction. In these patients, the ini-
tial lead-in with heparin facilitated the use of
rescue thrombolysis.
Does the Hokusai Study Provide Data
for the Extended Treatment
with Edoxaban in VTE Patients?
All patients with VTE should receive anticoag-
ulant treatment for a minimum of 3 months. At
this time, patients at increased risk of recur-
rence, such as those with unprovoked VTE or
previous VTE, should be considered for exten-
ded treatment duration [44]. A number of ‘‘ex-
tension’’ studies have suggested that dabigatran,
rivaroxaban, and apixaban are valid alternatives
to warfarin in this setting.
In the Hokusai-VTE study, all patients were
treated for a minimum of 3 months and were
followed for 12 months regardless of the
Fig. 5 Subgroup analysis in pulmonary embolism patients
with NT-proBNP C500 pg/mL. In 90% of Hokusai-VTE
patients with PE, NT-proBNP was measured at baseline.
Right ventricular (RV) dysfunction was deﬁned as a level
of C500 pg/mL. In PE patients with NT-proBNP levels
C500 pg/mL recurrent VTE occurred in 15 of 454
patients (3.3%) who received edoxaban and in 30 of 484
patients (6.2%) given warfarin [HR 0.52 (0.28–0.98)]. HR
hazard ratio, CI conﬁdence interval, VTE venous throm-
boembolism, PE pulmonary embolism, NT-proBNP
N-terminal prohormone of the brain natriuretic peptide
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intended or actual duration of therapy. The
decision on treatment duration beyond
3 months was left to the discretion of the
investigators, to simulate clinical practice. Thus,
although no formal ‘‘extension study’’ was
planned for edoxaban, the design of the Hoku-
sai study provided the opportunity to compare
edoxaban with warfarin for a prolonged treat-
ment of VTE. In a post-hoc analysis of the study
[46], the risk–benefit of anticoagulation with
edoxaban compared with warfarin was evalu-
ated in those patients who continued therapy
beyond 3 months. Among patients who
received edoxaban or warfarin, 88.2%
(n = 3633) and 87.2% (n = 3594), respectively,
continued treatment beyond 3 months; and
45.7% (n = 1661) and 46.2% (n = 1659),
respectively, were treated for 12 months. The
baseline characteristics of the two subgroups
who received extended therapy were compara-
ble. At 12 months, the cumulative incidence
rates of recurrent VTE were 1.8% in the edoxa-
ban group and 1.9% in the warfarin group (HR
0.97; 95% CI 0.69–1.37). The cumulative inci-
dences of major or non-major bleeding were
3.9% and 4.1%, respectively (HR 0.97; 95% CI
0.77–1.22); and the cumulative incidences of
major bleeding were 0.3% and 0.7%, respec-
tively (HR 0.45; 95% CI 0.22–0.92). These
results provide additional evidence that edoxa-
ban, administered OD, is an effective and safe
alternative to warfarin for VTE patients who
require anticoagulant treatment beyond
3 months.
EXPERT OPINION
In spite of the predictable anticoagulant effect
of NOACs, attention has been paid to the pos-
sibility that vulnerable patients might be
exposed to excess drug concentrations, which
might significantly increase the bleeding risk.
These concerns may have several implications
in the management of AF and VTE patients who
require an anticoagulation therapy, which
might lead to an inappropriate dose reduction
of NOACs, with a subsequent increase of
thromboembolic events.
The ENGAGE AF-TIMI 48 and the Hokusai
VTE are the largest trials ever conducted, with
the longest duration, in their setting, and both
considered reducing the dosage in patients with
high bleeding risk. Results demonstrating that
dose reduction provided an even greater differ-
ence in major bleeding with edoxaban versus
warfarin, while not altering its efficacy, suggest
that edoxaban might overcome these concerns.
The criteria adopted for dose reduction, based
on purely clinical information, allowed a proper
tailoring of the dose of edoxaban optimizing
the balance between the risks of thromboem-
bolic and bleeding events. Thus, a clear dose
strategy, together with the ease of use (owing to
the OD administration, few drug–drug interac-
tions, and no impact of food), might support
the use of edoxaban in a large spectrum of
patients, including the most vulnerable ones.
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